Deaths after gastric-balloon procedure for obesity investigated by FDA

In an alert issued Thursday, the FDA said that from 2016 to the present, five “unanticipated deaths” had occurred within a month or less in patients who had liquid-filled gastric balloon systems implanted in their stomachs.

The U.S. Food and Drug Administration (FDA) has alerted physicians and surgeons who treat obesity that it is investigating whether there is a link between gastric balloons — a new-generation weight-loss device — and the deaths of five patients.

In an alert issued Thursday, the FDA said that from 2016 to the present, five “unanticipated deaths” had occurred within a month or less in patients who had liquid-filled gastric-balloon systems implanted in their stomachs. In three of the cases, the agency said that patients died between one and three days after the weight-loss device had been put in place.

“At this time, we do not know the root cause or incidence rate of patient death, nor have we been able to definitively attribute the deaths to the devices or the insertion procedures for these devices,” the FDA told physicians.

The agency suggested it would explore the possibility that patients suffered gastric and esophageal perforation or intestinal obstruction, either while the device was being implanted or afterward.

Most Read Stories

Unlimited Digital Access. $1 for 4 weeks.

Four of the deaths involved the Orbera Intragastric Balloon System, manufactured by Apollo Endo Surgery of Austin, Texas, and approved by the FDA in August 2015. One of the reports involved the ReShape Integrated Dual Balloon System, manufactured by ReShape Medical in San Clemente, California, and approved by the FDA in July 2015.

The agency said it has received reports of two other deaths since 2016 related to potential complications associated with balloon treatment. In one of those deaths, a patient who had the Orbera Intragastric Balloon System implanted suffered a gastric perforation. In the second death a patient…

Read more from the source…

Back to Top